Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport area, marking a significant expansion in its research capabilities. The Lilly Seaport Innovation Center (LSC) spans 346,000 square feet and will accommodate 500 researchers, alongside 200 personnel involved in Lilly’s incubator initiative, Lilly Gateway Labs. Initially announced in 2022, the facility represents a substantial investment of $700 million, as highlighted by CEO Dave Ricks.
The new center aims to enhance R&D efforts in genetic medicine, with a particular focus on nucleic acid drugs, including RNA- and DNA-based therapies. Key therapeutic areas will encompass diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain.
The Lilly Gateway Labs incubator program, launched in San Francisco in 2019, has so far supported over 20 early-stage biotech companies, providing them with access to Lilly’s extensive R&D expertise and facilities, including wet labs.- Flcube.com
